+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Artemisinin Combination Therapy Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896064
  • Report
  • August 2020
  • Region: Global
  • 111 Pages
  • Mordor Intelligence


  • Cipla Ltd.
  • Desano Inc.
  • Hovid Berhad
  • KPC Pharmaceuticals
  • Novartis AG
  • Sanofi S.A.
Artemisinin combination therapy (ACT) is used for the treatment of Plasmodium falciparum malaria. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and under-developing countries.

According to the “World Malaria Report 2018” by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 related deaths in 2017 and most of the malaria cases were attributed to Plasmodium falciparum. Hence the high prevalence of malaria is driving the growth of this market. Other factors like an increase in awareness initiatives by governments and research for new anti-malarial drugs and therapies are also helping this market grow. However, side-effects of anti-malarial drugs and the presence of counterfeit and substandard drugs are restraining the growth of this market.

Key Market Trends

Artemether-Lumefantrine Segment is Expected to Dominate the Market During the Forecast Period

Artemether-Lumefantrine is a combination of the two medications artemether and lumefantrine. It is used to treat malaria caused by Plasmodium falciparum that is not treatable with chloroquine. They were both developed in China. It is one of the drugs on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

The World Health Organization recommends that uncomplicated Plasmodium falciparum malaria should be treated with an artemisinin- lumefantrine combination therapy. Artemether-lumefantrine is the most widely used Artemisinin Combination Therapy (ACT), accounting for 73% of global ACT procurement according to an article by Frank Kloprogge et al published in PLoS Medicine Journal 2018, which makes it one of the most widely used anti-infective agents in the world today. As this combination is used as the first-line drug for malaria in most countries, it is expected to cover a large share in the global artemisinin combination therapy market.

Middle East and Africa is Expected to Show a High Growth During the Forecast Period

The Middle East and Africa held the largest share in the artemisinin combination therapy market due to the presence of a large production base of artemisinin herbs and rising demand in malaria-endemic countries that are contributing to the growth of the market.

According to the World Health Organization (WHO), there were an estimated 219 million cases of malaria worldwide in 2017, out of which WHO African Region carried a disproportionately high share of the global malaria burden. In 2017, the region contributed 92% of malaria cases and 93% of malaria deaths. The WHO Eastern Mediterranean Region was home for nearly 2% of the global malaria cases. Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the artemisinin combination therapy market.

Competitive Landscape

Majority of the Artemisinin Combination Therapy drugs are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. These global players are mostly based in developed countries like United States, United Kingdom, France, Germany and Japan.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown


  • Cipla Ltd.
  • Desano Inc.
  • Hovid Berhad
  • KPC Pharmaceuticals
  • Novartis AG
  • Sanofi S.A.

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Malaria in Developing and Under Developed Countries
4.2.2 Awareness Initiatives Undertaken by the Governments
4.2.3 Increasing Research for New Drugs and New Combinations Therapies
4.3 Market Restraints
4.3.1 Side Effects of Anti-malaria Drugs
4.3.2 Presence of Counterfeit and Substandard Antimalarial Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Combination Therapy Type
5.1.1 Artemether-Lumefantrine
5.1.2 Artesunate-Amodiaquine
5.1.3 Artesunate-Pyronaridine
5.1.4 Artesunate-Sulfadoxine-Pyrimethamine
5.1.5 Others
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.2.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Cipla Ltd.
6.1.2 Desano Inc.
6.1.3 Hovid Berhad
6.1.4 KPC Pharmaceuticals
6.1.5 Guilin Pharmaceutical(Fosun Pharmaceutical )
6.1.6 Novartis AG
6.1.7 Sanofi S.A.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Cipla Ltd.
  • Desano Inc.
  • Hovid Berhad
  • KPC Pharmaceuticals
  • Guilin Pharmaceutical(Fosun Pharmaceutical )
  • Novartis AG
  • Sanofi S.A.
Note: Product cover images may vary from those shown